Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Analyst consensus and Net cash floor.
ACCE opinionvTv Therapeutics Inc. Class A Common Stock (VTVT)
Fair value
Not available
ACCE price target
$27.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $25.55 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
23
out of 100
Analysts
100% buy
7 covering
1-year return
+22.6%
Dividend yield
0.00%
vTv Therapeutics Inc. Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
vTv Therapeutics is a small clinical-stage biotech whose lead programmes target metabolic disease, including oral small molecules aimed at type 2 diabetes and obesity-related conditions. With a market capitalisation of about $109M, the company has no commercial product revenue to speak of, and its reported 22.2% gross margin and -25.1% operating margin reflect a royalty and licensing base that does not yet cover its research spend. The bull case rests on clinical readouts and partnering news that could validate the pipeline, but the data supplied here offers no revenue growth figure and no forward earnings, so the thesis depends entirely on pipeline milestones rather than current financials. The composite score of 22/100 sits in the weak range, and the stock carries no index membership, which limits passive demand. Worth a deeper look only if you are prepared to underwrite binary clinical and financing risk.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
severe
Heavy cash burn
Free cash flow of -$25.3M against a $110M market cap means the company burns roughly a fifth of its equity value each year. Operating margin is -25.1%.
high
No revenue growth
Revenue growth is 0.0% year over year and earnings growth is also 0.0%, with net margin at -12.9%. The business shows no sign yet of the top-line momentum needed to offset losses.
high
Score down sharply
The ACCE score fell 8 points over 90 days, from 31 to 23, with quality at 19 and value at 20. The deterioration is recent and broad.
AI research notes
AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-10-21 · prices to Oct 23, 2026
Why it could do well
Seven of seven analysts rate the stock Buy or Strong Buy, a unanimous view that the shares are worth buying.
Why it could disappoint
Free cash flow over the last twelve months was negative $25M, meaning the business burned cash rather than generating it.
The diluted share count rose 46.0% last fiscal year, diluting existing holders' stake in the company.
Earnings per share missed expectations by 40.0%, coming in at -1.05 against -0.75 forecast.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where VTVT's valuation models land
Price
$25.55
Model fair valueConfidence: low
about $42.99
Model
Fair value
Upside
Analyst consensus
Net cash floor
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores